Literature DB >> 9731501

Chimeric human-mouse IgG antibodies with shuffled constant region exons demonstrate that multiple domains contribute to in vivo half-life.

L S Zuckier1, C J Chang, M D Scharff, S L Morrison.   

Abstract

Structural features that determine the differing rates of immunoglobulin catabolism are of great relevance to the engineering of immunologically active reagents. Sequences in the CH2 and CH3 region of IgG have been shown to regulate the rate of clearance through their interaction with FcRn. In an attempt to probe additional structural features that regulate antibody half-life, we have investigated two families of chimeric antibodies, composed of identical murine heavy and light antidansyl variable regions joined to human kappa light-chains and wild-type or shuffled human IgG heavy-chain constant regions. These antibodies were iodinated, and their clearance was studied in severe combined immunodeficient mice hosts by whole-body radioactivity measurements. Clearances of the wild-type and recombinant antibodies were biphasic. In a panel of immunoglobulins derived from IgG2 and IgG3, as successive domains were varied from gamma2 to gamma3, beta-phase half-life gradually decreased from 337.0 h to 70.6 h. Statistical analysis suggested that the composition of each of the three domains affected half-life, and no single region of the molecule by itself determined the rate of clearance. In the second panel of immunoglobulins derived from IgG1 and IgG4, the construct with the amino terminus portion of the molecule derived from IgG4, joined within the CH2 domain to the COOH terminus portion of IgG1, had a half-life paradoxically greater than either IgG1, or IgG4 (P < 0.012). All four IgG1/IgG4 constructs demonstrated presence of the concentration catabolism phenomenon, which is a unique hallmark of immunoglobulin catabolism. The contribution of all three constant region domains to immunoglobulin half-life may be due to distant conformational effects in addition to direct binding to protective receptors, and emphasizes the importance of distant sequences on the rate of immunoglobulin catabolism. Interesting possibilities regarding mechanisms controlling immunoglobulin metabolism are raised by the hybrid gamma4/gamma1 molecule with a half-life greater than either parental immunoglobulin. Understanding the relationships between the structure of these molecules and their clearance rate will further our ability to produce immunoglobulins with improved pharmacokinetic properties.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9731501

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

Review 1.  Transcytosis and catabolism of antibody.

Authors:  Victor Ghetie; E Sally Ward
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 2.  Recombinant antibodies for the diagnosis and treatment of cancer.

Authors:  Jürgen Krauss
Journal:  Mol Biotechnol       Date:  2003-09       Impact factor: 2.695

Review 3.  Antibody vectors for imaging.

Authors:  Tove Olafsen; Anna M Wu
Journal:  Semin Nucl Med       Date:  2010-05       Impact factor: 4.446

Review 4.  Antibody-Drug Conjugates: Pharmacokinetic/Pharmacodynamic Modeling, Preclinical Characterization, Clinical Studies, and Lessons Learned.

Authors:  William D Hedrich; Tamer E Fandy; Hossam M Ashour; Hongbing Wang; Hazem E Hassan
Journal:  Clin Pharmacokinet       Date:  2018-06       Impact factor: 6.447

5.  Anti-CD20-interferon-β fusion protein therapy of murine B-cell lymphomas.

Authors:  Kham R Trinh; Alex Vasuthasawat; Kristopher K Steward; Reiko E Yamada; John M Timmerman; Sherie L Morrison
Journal:  J Immunother       Date:  2013-06       Impact factor: 4.456

6.  Platelet factor 4 is a negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implications.

Authors:  Michele P Lambert; Lubica Rauova; Matthew Bailey; Martha C Sola-Visner; M Anna Kowalska; Mortimer Poncz
Journal:  Blood       Date:  2007-05-10       Impact factor: 22.113

7.  Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas.

Authors:  Tove Olafsen; David Betting; Vania E Kenanova; Felix B Salazar; Pat Clarke; Jonathan Said; Andrew A Raubitschek; John M Timmerman; Anna M Wu
Journal:  J Nucl Med       Date:  2009-08-18       Impact factor: 10.057

8.  Molecularly defined antibody conjugation through a selenocysteine interface.

Authors:  Thomas Hofer; Lauren R Skeffington; Colby M Chapman; Christoph Rader
Journal:  Biochemistry       Date:  2009-12-22       Impact factor: 3.162

9.  Development of antihuman IgG antibodies and hematologic deficits but not clinical abnormalities in C57BL/6 mice after repeated administration of human intravenous immunoglobulin.

Authors:  David A Loeffler; Lynnae M Smith; Andrea C Klaver; Heather A Brzezinski; Essie I Morrison; Mary P Coffey; Barbara A Steficek; Susan S Cook
Journal:  Comp Med       Date:  2012-02       Impact factor: 0.982

10.  Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC.

Authors:  Akito Natsume; Rinpei Niwa; Mitsuo Satoh
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.